Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
It is not often that the results of clinical trials change clinical practice almost overnight. But that is what has happened with two clinical trials (Delta and ACTG175) of combination nucleoside analogue antiretroviral treatment for patients infected with HIV. The previously standard monotherapy had evident limitations in the extent and durability of response. The need for and expectations of better treatments was high, fuelling but also distorting the investigation of improved approaches. What are the practical implications of these studies?
Delta (conducted by a European/Australian group coordinated by Britain's Medical Research Council and the Agence National de Recherches sur le SIDA in France) and ACTG175 (conducted in the United States by the AIDS Clinical Trials Group of the National Institutes of Health) have recently released their main findings. They were large randomised double blind placebo controlled trials of zidovudine
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?